Phase II Study of Pembrolizumab in Combination With BCG After Endoscopic Ablation for Patients With High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma Unfit or Unwilling to be Treated With Nephroureterectomy
Latest Information Update: 02 Feb 2023
At a glance
- Drugs BCG (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 04 Jan 2023 Status changed from not yet recruiting to discontinued.
- 20 Nov 2017 New trial record